98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278676 | PMC |
http://dx.doi.org/10.1002/acm2.13701 | DOI Listing |
Br J Clin Pharmacol
September 2025
Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University Sofia, Sofia, Bulgaria.
Aims: Late-diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost-benefit of screening programmes for DR.
View Article and Find Full Text PDFHealth Promot Pract
September 2025
Center for Nutrition & Health Impact, Omaha, NE, USA.
The U.S. foundations contribute billions of dollars each year to community-based organizations (CBOs).
View Article and Find Full Text PDFPLoS One
September 2025
Wildlife and Fisheries Biology Program, Rubenstein School of Environment and Natural Resources, University of Vermont, Burlington, Vermont, United States of America.
Landscape connectivity is often negatively impacted by road networks that fragment habitat and result in genetic and demographic consequences for wildlife. Existing roadway structures like bridges, culverts, and underpasses can facilitate connectivity and reduce the barrier effect of roads by providing less risky areas for animals to cross. Estimating areas of high wildlife movement near roads is beneficial for prioritizing transportation investments for wildlife.
View Article and Find Full Text PDFBackground: Photon-counting detector computed tomography (PCD CT) offers higher dose efficiency than conventional energy-integrating detector CT (EID CT), which is particularly beneficial for children. Broad evidence is missing whether frequently acquired pediatric low-dose lung imaging can be further improved using PCD CT.
Objective: To compare radiation exposure, quantitative and qualitative image quality of pediatric low-dose chest PCD CT versus EID CT examinations.
Alzheimers Dement
September 2025
Cleveland Clinic Genome Center, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Introduction: Glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors have potential beneficial effects in Alzheimer's disease (AD).
Methods: We conducted pharmacoepidemiologic studies using two large-scale real-world databases. We fitted covariate-adjusted Cox models to compare the risks of AD among initiators of GLP-1 receptor agonists, SGLT-2 inhibitors, and DPP-4 inhibitors.